119 related articles for article (PubMed ID: 29658609)
1. Survivin knockdown induces senescence in TTF‑1-expressing, KRAS-mutant lung adenocarcinomas.
Sumi T; Hirai S; Yamaguchi M; Tanaka Y; Tada M; Yamada G; Hasegawa T; Miyagi Y; Niki T; Watanabe A; Takahashi H; Sakuma Y
Int J Oncol; 2018 Jul; 53(1):33-46. PubMed ID: 29658609
[TBL] [Abstract][Full Text] [Related]
2. A combinatorial strategy for treating KRAS-mutant lung cancer.
Manchado E; Weissmueller S; Morris JP; Chen CC; Wullenkord R; Lujambio A; de Stanchina E; Poirier JT; Gainor JF; Corcoran RB; Engelman JA; Rudin CM; Rosen N; Lowe SW
Nature; 2016 Jun; 534(7609):647-51. PubMed ID: 27338794
[TBL] [Abstract][Full Text] [Related]
3. Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A; Rodríguez-Remírez M; López I; Macaya I; Guruceaga E; Olmedo M; Vilalta-Lacarra A; Welch C; Sandiego S; Vicent S; Valencia K; Calvo A; Pio R; Raez LE; Rolfo C; Ajona D; Gil-Bazo I
Mol Cancer; 2024 Apr; 23(1):78. PubMed ID: 38643157
[TBL] [Abstract][Full Text] [Related]
4. Deubiquitinase USP18 Loss Mislocalizes and Destabilizes KRAS in Lung Cancer.
Mustachio LM; Lu Y; Tafe LJ; Memoli V; Rodriguez-Canales J; Mino B; Villalobos PA; Wistuba I; Katayama H; Hanash SM; Roszik J; Kawakami M; Cho KJ; Hancock JF; Chinyengetere F; Hu S; Liu X; Freemantle SJ; Dmitrovsky E
Mol Cancer Res; 2017 Jul; 15(7):905-914. PubMed ID: 28242811
[No Abstract] [Full Text] [Related]
5. Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors.
Corcoran RB; Do KT; Kim JE; Cleary JM; Parikh AR; Yeku OO; Xiong N; Weekes CD; Veneris J; Ahronian LG; Mauri G; Tian J; Norden BL; Michel AG; Van Seventer EE; Siravegna G; Camphausen K; Chi G; Fetter IJ; Brugge JS; Chen H; Takebe N; Penson RT; Juric D; Flaherty KT; Sullivan RJ; Clark JW; Heist RS; Matulonis UA; Liu JF; Shapiro GI
Clin Cancer Res; 2024 May; 30(9):1739-1749. PubMed ID: 38456660
[TBL] [Abstract][Full Text] [Related]
6. FOSL1 Promotes Kras-induced Lung Cancer through Amphiregulin and Cell Survival Gene Regulation.
Elangovan IM; Vaz M; Tamatam CR; Potteti HR; Reddy NM; Reddy SP
Am J Respir Cell Mol Biol; 2018 May; 58(5):625-635. PubMed ID: 29112457
[TBL] [Abstract][Full Text] [Related]
7. An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2.
Cardnell RJ; Behrens C; Diao L; Fan Y; Tang X; Tong P; Minna JD; Mills GB; Heymach JV; Wistuba II; Wang J; Byers LA
Clin Cancer Res; 2015 Aug; 21(15):3480-91. PubMed ID: 25878335
[TBL] [Abstract][Full Text] [Related]
8. Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
Skoulidis F; Byers LA; Diao L; Papadimitrakopoulou VA; Tong P; Izzo J; Behrens C; Kadara H; Parra ER; Canales JR; Zhang J; Giri U; Gudikote J; Cortez MA; Yang C; Fan Y; Peyton M; Girard L; Coombes KR; Toniatti C; Heffernan TP; Choi M; Frampton GM; Miller V; Weinstein JN; Herbst RS; Wong KK; Zhang J; Sharma P; Mills GB; Hong WK; Minna JD; Allison JP; Futreal A; Wang J; Wistuba II; Heymach JV
Cancer Discov; 2015 Aug; 5(8):860-77. PubMed ID: 26069186
[TBL] [Abstract][Full Text] [Related]
9. Suppression of interferon gene expression overcomes resistance to MEK inhibition in KRAS-mutant colorectal cancer.
Wagner S; Vlachogiannis G; De Haven Brandon A; Valenti M; Box G; Jenkins L; Mancusi C; Self A; Manodoro F; Assiotis I; Robinson P; Chauhan R; Rust AG; Matthews N; Eason K; Khan K; Starling N; Cunningham D; Sadanandam A; Isacke CM; Kirkin V; Valeri N; Whittaker SR
Oncogene; 2019 Mar; 38(10):1717-1733. PubMed ID: 30353166
[TBL] [Abstract][Full Text] [Related]
10. A Deregulated HOX Gene Axis Confers an Epigenetic Vulnerability in KRAS-Mutant Lung Cancers.
Guerra SL; Maertens O; Kuzmickas R; De Raedt T; Adeyemi RO; Guild CJ; Guillemette S; Redig AJ; Chambers ES; Xu M; Tiv H; Santagata S; Jänne PA; Elledge SJ; Cichowski K
Cancer Cell; 2020 May; 37(5):705-719.e6. PubMed ID: 32243838
[TBL] [Abstract][Full Text] [Related]
11. Farnesyl-transferase inhibitors show synergistic anticancer effects in combination with novel KRAS-G12C inhibitors.
Baranyi M; Molnár E; Hegedűs L; Gábriel Z; Petényi FG; Bordás F; Léner V; Ranđelović I; Cserepes M; Tóvári J; Hegedűs B; Tímár J
Br J Cancer; 2024 Apr; 130(6):1059-1072. PubMed ID: 38278976
[TBL] [Abstract][Full Text] [Related]
12. Insulin receptor substrate-1 deficiency drives a proinflammatory phenotype in KRAS mutant lung adenocarcinoma.
Metz HE; Kargl J; Busch SE; Kim KH; Kurland BF; Abberbock SR; Randolph-Habecker J; Knoblaugh SE; Kolls JK; White MF; Houghton AM
Proc Natl Acad Sci U S A; 2016 Aug; 113(31):8795-800. PubMed ID: 27439864
[TBL] [Abstract][Full Text] [Related]
13. Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress.
Shimomura I; Watanabe N; Yamamoto T; Kumazaki M; Tada Y; Tatsumi K; Ochiya T; Yamamoto Y
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33830081
[TBL] [Abstract][Full Text] [Related]
14. E-Cadherin Loss Accelerates Tumor Progression and Metastasis in a Mouse Model of Lung Adenocarcinoma.
Sinkevicius KW; Bellaria KJ; Barrios J; Pessina P; Gupta M; Brainson CF; Bronson RT; Kim CF
Am J Respir Cell Mol Biol; 2018 Aug; 59(2):237-245. PubMed ID: 29447458
[TBL] [Abstract][Full Text] [Related]
15. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras.
Yang Y; Wislez M; Fujimoto N; Prudkin L; Izzo JG; Uno F; Ji L; Hanna AE; Langley RR; Liu D; Johnson FM; Wistuba I; Kurie JM
Mol Cancer Ther; 2008 Apr; 7(4):952-60. PubMed ID: 18413809
[TBL] [Abstract][Full Text] [Related]
16. FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung.
Tomoshige K; Stuart WD; Fink-Baldauf IM; Ito M; Tsuchiya T; Nagayasu T; Yamatsuji T; Okada M; Fukazawa T; Guo M; Maeda Y
Cancer Res; 2023 May; 83(9):1443-1458. PubMed ID: 37067057
[TBL] [Abstract][Full Text] [Related]
17. Activation of KrasG12D in Subset of Alveolar Type II Cells Enhances Cellular Plasticity in Lung Adenocarcinoma.
Chaudhary P; Xu X; Wang G; Hoj JP; Rampersad RR; Asselin-Labat ML; Ting S; Kim W; Tamayo P; Pendergast AM; Onaitis MW
Cancer Res Commun; 2023 Nov; 3(11):2400-2411. PubMed ID: 37882674
[TBL] [Abstract][Full Text] [Related]
18. Requirement for interaction of PI3-kinase p110α with RAS in lung tumor maintenance.
Castellano E; Sheridan C; Thin MZ; Nye E; Spencer-Dene B; Diefenbacher ME; Moore C; Kumar MS; Murillo MM; Grönroos E; Lassailly F; Stamp G; Downward J
Cancer Cell; 2013 Nov; 24(5):617-30. PubMed ID: 24229709
[TBL] [Abstract][Full Text] [Related]
19. Elevated expression of JAM-A promotes neoplastic properties of lung adenocarcinoma.
Magara K; Takasawa A; Osanai M; Ota M; Tagami Y; Ono Y; Takasawa K; Murata M; Hirohashi Y; Miyajima M; Yamada G; Hasegawa T; Sawada N
Cancer Sci; 2017 Nov; 108(11):2306-2314. PubMed ID: 28837251
[TBL] [Abstract][Full Text] [Related]
20. K-ras 4A and 4B mRNA levels correlate with superoxide in lung adenocarcinoma cells, while at the protein level, only mutant K-ras 4A protein correlates with superoxide.
Calvert RJ; Gupta M; Maciag A; Shiao YH; Anderson LM
Lung Cancer; 2013 Jun; 80(3):263-9. PubMed ID: 23474128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]